|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||69.04 - 69.81|
|52 Week Range||57.14 - 69.96|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.62%|
We have highlighted five solid picks from both the ETF and the stock world that were in red over the past week but have a Zacks Rank #1 or 2.
First Trust Advisors L.P. a global exchange-traded fund provider and asset manager, announced that the Mexican pension funds investment regulator, La Comisión Nacional del Sistema de Ahorro para el Retiro , has approved four additional First Trust ETFs for sale to Mexican funded pensions, known as AFORES.
Health-care stocks finished dead last in the Standard & Poor's 500 as Republicans tried yet again to repeal and replace the Affordable Care Act. The Cassidy-Graham bill, named for Senator Bill Cassidy, R-La., and Lindsey Graham, R-S.C., was introduced Sept. 13 and appears to be gaining momentum. Cassidy-Graham would get rid of individual and employer mandates and subsidies and rollback Medicaid, among other things.
In 2Q17, United Therapeutics’ (UTHR) Remodulin generated revenues of around $158 million, which reflected ~8% growth on a quarter-over-quarter basis.
For the quarter ending March 31, 2017, Abiomed (ABMD) reported revenues close to $124.7 million, which represents a YoY growth of about 30%.
For fiscal 2017, Align Technology (ALGN) expects its 2017 revenues to grow operationally in the range of 15%–25% YoY.
WellCare Health Plans has updated its earnings per share guidance from the previously estimated range of $6.00–$6.25 to the new range of $6.55–$6.80.
Dentsply Sirona’s (XRAY) 1Q17 earnings and revenue failed to meet analysts’ estimates. The company reported a fall in its organic revenue.
House Republicans have released the long-awaited bill to repeal and replace Obama's signature healthcare law last evening. This will unwind much of the law over the next three years.
The President is expected to bring more clarity on promised tax cuts, big spending, and other business friendly policies in his first speech to Congress slated to be held later today.
Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.
As noted in separate articles on ETF.com this month, annual flows into U.S.-listed exchange-traded funds are in record territory, and it's the giant broad market ETFs―such as the SPDR S&P 500 ETF (SPY)―that have been the most popular funds in 2016.